262 related articles for article (PubMed ID: 19106059)
1. An alternate explanation for the decrease in pemphigus antibodies with combination treatment of double-filtration plasmapheresis and IVIg.
Habib N; Bystryn JC
Eur J Dermatol; 2009; 19(2):190; author reply 191. PubMed ID: 19106059
[No Abstract] [Full Text] [Related]
2. Severe pemphigus vulgaris: successful combination therapy of plasmapheresis followed by intravenous high-dose immunoglobulin to prevent rebound increase in pathogenic IgG.
Aoyama Y; Nagasawa C; Nagai M; Kitajima Y
Eur J Dermatol; 2008; 18(5):557-60. PubMed ID: 18693160
[TBL] [Abstract][Full Text] [Related]
3. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins.
Shimanovich I; Nitschke M; Rose C; Grabbe J; Zillikens D
Br J Dermatol; 2008 Feb; 158(2):382-8. PubMed ID: 18070210
[TBL] [Abstract][Full Text] [Related]
4. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis.
Liu JF; Wang WX; Xue J; Zhao CB; You HZ; Lu JH; Gu Y
Ther Apher Dial; 2010 Apr; 14(2):153-60. PubMed ID: 20438536
[TBL] [Abstract][Full Text] [Related]
5. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris.
Bystryn JC; Jiao D
Autoimmunity; 2006 Nov; 39(7):601-7. PubMed ID: 17101504
[TBL] [Abstract][Full Text] [Related]
6. Catabolism of pemphigus foliaceus autoantibodies by high-dose IVIg therapy.
Aoyama Y; Moriya C; Kamiya K; Nagai M; Rubenstein D; Iwatsuki K; Kitajima Y
Eur J Dermatol; 2011; 21(1):58-61. PubMed ID: 21233063
[TBL] [Abstract][Full Text] [Related]
7. Clearance efficacy of autoantibodies in double filtration plasmapheresis for pemphigus foliaceus.
Kasuya A; Moriki M; Tatsuno K; Hirakawa S; Tokura Y
Acta Derm Venereol; 2013 Mar; 93(2):181-2. PubMed ID: 22948906
[No Abstract] [Full Text] [Related]
8. [Treatment of pemphigus vulgaris with plasmapheresis].
Woscoff A; Di Lonardo AM; Remondino G; Carballo G; Laviano N; Ledesma L; Jaimovich L
Medicina (B Aires); 1988; 48(4):395-400. PubMed ID: 3255031
[No Abstract] [Full Text] [Related]
9. Recalcitrant pemphigus herpetiformis with high titer of immunoglobulin G antibody to desmoglein 1 and positive IgG antibody to desmocollin 3, elevating thymus and activation-regulated chemokine.
Matsukura S; Takahashi K; Hirokado M; Ikezawa Y; Nakamura K; Fukuda S; Hashimoto T; Ikezawa Z; Aihara M; Kambara T
Int J Dermatol; 2014 Aug; 53(8):1023-6. PubMed ID: 23432082
[No Abstract] [Full Text] [Related]
10. [High-dose intravenous immunoglobulin (IVIG) for autoimmune bullous diseases].
Ishii N; Hashimoto T
Arerugi; 2010 Dec; 59(12):1605-9. PubMed ID: 21212725
[No Abstract] [Full Text] [Related]
11. [Plasmapheresis in the treatment of pemphigus].
Blaszczyk M; Chorzelski T; Daszynski J; Jabłońska S; Beutner EH
Z Hautkr; 1985 Aug; 60(15):1175-82. PubMed ID: 4049988
[TBL] [Abstract][Full Text] [Related]
12. Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus.
Czernik A; Beutner EH; Bystryn JC
J Am Acad Dermatol; 2008 May; 58(5):796-801. PubMed ID: 18423257
[TBL] [Abstract][Full Text] [Related]
13. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris.
Turner MS; Sutton D; Sauder DN
J Am Acad Dermatol; 2000 Dec; 43(6):1058-64. PubMed ID: 11100023
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs.
Grando SA
Int J Dermatol; 2019 Jan; 58(1):114-125. PubMed ID: 30047585
[TBL] [Abstract][Full Text] [Related]
15. What's new in i.v. immunoglobulin therapy and pemphigus: high-dose i.v. immunoglobulin therapy and its mode of action for treatment of pemphigus.
Aoyama Y
J Dermatol; 2010 Mar; 37(3):239-45. PubMed ID: 20507387
[TBL] [Abstract][Full Text] [Related]
16. Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris.
Green MG; Bystryn JC
Arch Dermatol; 2008 Dec; 144(12):1621-4. PubMed ID: 19075146
[TBL] [Abstract][Full Text] [Related]
17. [Continuous plasma filtration. Experiences in the treatment of pemphigus vulgaris].
Vennemann F; Schedel A; Lorenzen M
Z Hautkr; 1984 Aug; 59(16):1075-9. PubMed ID: 6485455
[TBL] [Abstract][Full Text] [Related]
18. Current therapy of the pemphigus group.
Kasperkiewicz M; Schmidt E; Zillikens D
Clin Dermatol; 2012; 30(1):84-94. PubMed ID: 22137231
[TBL] [Abstract][Full Text] [Related]
19. An 'n-of-1' placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris.
Arnold DF; Burton J; Shine B; Wojnarowska F; Misbah SA
Br J Dermatol; 2009 May; 160(5):1098-102. PubMed ID: 19222460
[TBL] [Abstract][Full Text] [Related]
20. Synchronization of plasmapheresis and pulse cyclophosphamide therapy in pemphigus vulgaris.
Euler HH; Löffler H; Christophers E
Arch Dermatol; 1987 Sep; 123(9):1205-10. PubMed ID: 3632005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
